FAQ

No. Tempus can only be ordered by your physician.

Knowing the alterations that are driving your cancer may help to identify targeted FDA-approved and clinical trial therapies that in some cases have been proven to be more effective than organ- and tissue-specific treatments.

Your doctor will need to order the test directly from Tempus by completing a simple requisition form. We will coordinate the collection of specimen samples (blood or saliva, as necessary) and will request the tumor sample from your hospital’s pathology department.

From the time Tempus receives the necessary specimen samples, it typically takes approximately two to three weeks to sequence and generate your report. The report will be delivered to your physician, who will contact you when the results are received.

We will work with your insurance company to submit for reimbursement. A comprehensive patient-assistance program is also available. Apply for assistance at access.tempus.com.

If unable to complete the online application, please contact our Client Services team at 800-739-4137 for assistance.

We will work with your hospitalʼs pathology department to obtain your tissue sample. Your tumor sample will be sent to our secure sequencing lab in Chicago.

We generate a comprehensive report that will present your tumor biology, potential targeted therapies and your patient history. The report will also highlight recruiting clinical trials, if available, that fit your profile. We also provide other insights for deeper exploration of available options.

The report will be sent to your physician to share with you.

Our services explore options for patients with metastatic, refractory and recurrent cancer. Eligible patients include those with cancer of unknown origin; rare or uncommon solid tumors with limited treatment options; solid tumors not responding to standard of care; recurrent or metastatic cancer, or an interest in enrolling in clinical trials. It’s up to your doctor to decide if genetic sequencing can help in your cancer treatment.

Our comprehensive approach checks hundreds of genes for alterations by testing both the tumor tissue DNA and the normal tissue DNA along with testing the RNA. By testing all three together, we improve the detection of tumor-specific alterations and take a deep look into your tumor’s biology.